EIC Pathfinder Challenges 2026: Biotechnology for Healthy Ageing
Last Friday, March 20, 2026, the European Innovation Council (EIC) presented the new challenges for the 2026 Pathfinder programme in a series of dedicated webinars. One of these challenges is Biotechnology for Healthy Ageing, a topic that reflects both scientific progress and growing societal urgency.
At its core, this challenge remains a classic Pathfinder call: a Research and Innovation Action aimed at developing early-stage proof of concept for radically new technologies. Projects are expected to explore cutting-edge scientific directions with the potential to disrupt existing markets or create entirely new ones.
From treating diseases to targeting ageing itself
The EIC Pathfinder 2026 challenge is rooted in a clear observation: societies are ageing rapidly, and many of today’s most pressing diseases, such as cardiovascular disease, diabetes, cancer and Alzheimer’s, are closely linked to ageing. Traditionally, these conditions are addressed individually. However, advances in our understanding of the molecular and cellular mechanisms of ageing are opening up a different approach, targeting ageing itself as the underlying driver.
The EIC explicitly embraces this shift, encouraging projects that move beyond disease-specific treatment towards interventions that address root causes.
Three complementary innovation pathways
To structure this ambition, the challenge is divided into three distinct but interconnected pathways. Each project is expected to deliver proof of concept in one of the following areas:
- A biotechnology or pharmaceutical intervention to prevent, delay or reverse the onset of a specific age-related disease;
- A biomarker-based tool to support the responsible deployment of ageing-related interventions;
- A novel New Approach Methodology (NAM) that advances the state of the art and enables future development of healthy ageing interventions.
This design is noteworthy. Rather than focusing solely on breakthrough therapies, the EIC explicitly includes enabling technologies such as biomarkers and NAMs. This reflects a broader understanding: without robust validation tools and translational pathways, even the most promising interventions are unlikely to reach real-world impact.
Strong emphasis on implementation and uptake
A striking aspect of this challenge is its consistent focus on feasibility and downstream uptake. Across all project types, applicants are expected to develop new technological proof of concepts and to actively consider how they can be further developed toward later TRL stages and implemented in practice.
This is reflected in several requirements:
- Projects should accelerate implementation, outline regulatory pathways, and contribute to improving citizen literacy around longevity;
- Although biotechnology and pharmaceutical interventions must be validated in vertebrate models, projects should also anticipate future clinical testing strategies;
- All projects are expected to include a credible exploitation plan, addressing ethical, societal, economic and regulatory dimensions;
- Biomarker tools must demonstrate clear deployment feasibility and incorporate user feedback;
- NAMs should capture the systemic and age-related nature of ageing, be validated in a concrete use case, and be benchmarked against relevant animal models;
- Sex- and gender-specific effects must be considered across all approaches;
In addition, while shorter projects are allowed, the EIC explicitly recommends using the full five-year duration to maximise the chances of achieving meaningful results.
A maturing Pathfinder approach
Taken together, this challenge illustrates how the Pathfinder programme continues to mature. While the EIC has always emphasised that research should lay the foundation for future innovation, this call makes that expectation more explicit and operational than before. Scientific excellence and breakthrough potential remain central, but there is a stronger and more structured focus on credible pathways to impact. The inclusion of enabling technologies, regulatory considerations, and societal aspects reflects a more integrated view on how early-stage research can translate into real-world applications. For applicants, this means that strong science alone is not enough. Proposals must clearly demonstrate how their concept can evolve beyond proof of principle, and how barriers to implementation are anticipated from the outset.
Curious what our specialists could do for your project? Get in contact and we are happy to discuss your opportunities. Get in contact via info@hezelburcht.com or call 088 495 20 00 or fill in the contactform.
